keyword
MENU ▼
Read by QxMD icon Read
search

HIPEC and Gastric

keyword
https://www.readbyqxmd.com/read/28643069/lessons-learned-from-a-phase-ii-clinical-trial-of-laparoscopic-hipec-for-gastric-cancer
#1
Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Keith Fournier, Richard Royal, Paul Mansfield, Jaffer Ajani
BACKGROUND: Over the last two decades, intraperitoneal chemotherapy has been found to have activity for select subgroups of patients with carcinomatosis from colon, ovarian, appendiceal, and recently, gastric origins. However, there is little data to support an aggressive surgical approach of cytoreduction (debulking) and hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) for patients with gastric cancer and positive cytology or carcinomatosis. The morbidity and mortality rates of cytoreduction and HIPEC, in combination with gastrectomy, are significant and the survival rates of this approach may not extend beyond that of treatment with systemic chemotherapy...
June 22, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28540827/complete-cytoreductive-surgery-plus-hipec-for-peritoneal-metastases-from-unusual-cancer-sites-of-origin-results-from-a-worldwide-analysis-issue-of-the-peritoneal-surface-oncology-group-international-psogi
#2
Diane Goéré, Guillaume Passot, Maximiliano Gelli, Edward A Levine, David L Bartlett, Paul H Sugarbaker, Olivier Glehen
AIM: The aim of this study was to assess the outcomes of patients operated on for peritoneal metastases from unusual cancer sites of origin, meaning apart from PM from colorectal, gastric and epithelial ovarian carcinomas, pseudomyxoma peritonei and mesothelioma. PATIENTS AND METHODS: A questionnaire concerning patients treated with CRS plus HIPEC for PM arising from unusual cancer sites of origin was sent to all centers that routinely performed HIPEC, through the Peritoneal Surface Oncology Group International and the RENAPE network...
March 8, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540826/drugs-doses-and-durations-of-intraperitoneal-chemotherapy-standardizing-hipec-and-epic-for-colorectal-appendiceal-gastric-ovarian-peritoneal-surface-malignancies-and-peritoneal-mesothelioma
#3
Lieselotte Lemoine, Paul Sugarbaker, Kurt Van der Speeten
Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization amongst the various IP chemotherapy treatment modalities used today in clinical practice...
February 8, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28507577/peritoneal-lavage-examination-as-a-prognostic-tool-in-cases-of-gastric-cancer
#4
David Hoskovec, Jozef Varga, Petr Dytrych, Ellen Konecna, Jan Matek
INTRODUCTION: Peritoneal tumor seeding is a common form of recurrence after gastric cancer surgery. The finding of free tumor cells and/or elevation of tumor markers in the peritoneal fluid could predict intraperitoneal tumor recurrence. The results of these examination can be used for indication of aggressive treatment modalities such as hyperthermic intraperitoneal chemotherapy (HIPEC). MATERIAL AND METHODS: We have operated on 105 patients suffering from gastric cancer...
April 1, 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28501134/factors-associated-with-palliative-care-use-in-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#5
Rachel S Morris, Faiz Gani, Abdulrahman Y Hammad, Wendy Peltier, T Clark Gamblin, Kiran K Turaga, Fabian M Johnston
BACKGROUND: Peritoneal carcinomatosis represents widespread metastatic disease throughout the abdomen and/or pelvis. Cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) improves the overall survival compared to standard therapy alone. The role palliative care (PC) plays however, remains poorly studied among these patients. METHODS: Patients who had previously undergone HIPEC and who underwent an inpatient admission from 7/1/2013 to 6/30/2014 were identified to determine which patients were referred for inpatient or outpatient palliative consultation...
May 1, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28456089/the-30-year-experience-a-meta-analysis-of-randomised-and-high-quality-non-randomised-studies-of-hyperthermic-intraperitoneal-chemotherapy%C3%A2-in-the-treatment-of-gastric-cancer
#6
REVIEW
Jacopo Desiderio, Joseph Chao, Laleh Melstrom, Susanne Warner, Federico Tozzi, Yuman Fong, Amilcare Parisi, Yanghee Woo
IMPORTANCE: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used within various multimodality strategies for the prevention and treatment of gastric cancer peritoneal carcinomatosis. OBJECTIVE: To systematically evaluate the role of HIPEC in gastric cancer and clarify its effectiveness at different stages of peritoneal disease progression. DATA SOURCES: Medline and Embase databases between January 1, 1985 and June 1, 2016. STUDY SELECTION: Randomised control trials and high-quality non-randomised control trials selected on a validated tool (methodological index for non-randomised studies) comparing HIPEC and standard oncological management for the treatment of advanced stage gastric cancer with and without peritoneal carcinomatosis were considered...
July 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28415645/peritoneal-carcinomatosis-limits-of-diagnosis-and-the-case-for-liquid-biopsy
#7
REVIEW
James R W McMullen, Matthew Selleck, Nathan R Wall, Maheswari Senthil
Peritoneal Carcinomatosis (PC) is a late stage manifestation of several gastrointestinal malignancies including appendiceal, colorectal, and gastric cancer. In PC, tumors metastasize to and deposit on the peritoneal surface and often leave patients with only palliative treatment options. For colorectal PC, median survival is approximately five months, and palliative systemic therapy is able to extend this to approximately 12 months. However, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) with a curative intent is possible in some patients with limited tumor burden...
March 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28373757/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-treatment-of-gastric-cancer-with-peritoneal-carcinomatosis
#8
Lynne M Ellison, Yangao Man, Alexander Stojadinovic, Hongwu Xin, Itzhak Avital
Although gastric cancer with peritoneal carcinomatosis is associated with poor prognosis and is generally treated with palliative systemic therapy, recent studies have shown that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may prove to be an efficacious treatment option. In addition to reviewing the natural history of gastric cancer with peritoneal carcinomatosis, this mini-review examines literature on the efficacy of CRS and HIPEC as compared to chemotherapy and surgical options...
February 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/28187769/gastric-perforation-following-cytoreductive-surgery-and-perioperative-intraperitoneal-chemotherapy-a-case-series-of-six
#9
Lee S Kyang, Nayef A Alzahrani, Jing Zhao, David L Morris
BACKGROUND: Incidence of gastric perforation following cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) is not widely reported. METHODS: Suitable patients were identified from our database of 1028 procedures. Relevant information was then gathered via medical records and operation reports for these patients. RESULTS: Six patients suffered early postoperative gastric perforation following the procedure (0.58%), all of whom received heated intraoperative intraperitoneal chemotherapy (HIPEC)...
February 10, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28133187/-stage-iv-gastric-cancer-with-positive-peritoneal-washing-cytology-or-peritoneal-dissemination-was-successfully-treated-with-gastrectomy-and-hyperthermic-intraperitoneal-chemotherapy-hipec-followed-by-systemic-chemotherapy-a-report-of-two-cases
#10
Tsuyoshi Yamaguchi, Satoshi Murata, Sachiko Kaida, Reiko Ohtake, Katsushi Takebayashi, Hiroshi Yamamoto, Toru Miyake, Hiroya Akabori, Hiromichi Sonoda, Tsuyoshi Mori, Tomoharu Shimizu, Shigeyuki Naka, Suzuko Moritani, Ryoji Kushima, Masaji Tani
Survival of Stage IV gastric cancer is poor. We report 2 cases of Stage IV gastric cancer with positive peritoneal washing cytology or peritoneal dissemination that were successfully treated with gastrectomy and hyperthermic intraperitoneal chemotherapy( HIPEC)followed by systemic chemotherapy. Case 1: A 59-year-old woman. She was diagnosed with advanced gastric cancer and underwent gastrectomy with HIPEC. Her peritoneal washing cytology was positive during the gastrectomy. After the surgery, she underwent chemotherapy consisting of 8 courses of combination S-1 plus CPT-11 and 19 courses of PTX...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28124576/current-status-and-future-prospects-of-clinical-trials-on-crs-hipec-for-gastric-cancer-peritoneal-metastases
#11
Zhong-He Ji, Kai-Wen Peng, Yang Yu, Xin-Bao Li, Yutaka Yonemura, Yang Liu, Paul H Sugarbaker, Yan Li
PURPOSE: There is no standard treatment for peritoneal metastases (PM) from gastric cancer (GC). The aim of this review is to evaluate the clinical trials on cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for GC PM. MATERIALS AND METHODS: The published clinical trials on CRS + HIPEC for GC PM are critically evaluated, and survival and safety are the primary endpoints. In addition, the registered ongoing clinical trials are summarized...
January 26, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28098079/hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-surface-malignancies-a-single-institution-indian-experience
#12
S P Somashekhar, G Prasanna, Rajshekhar Jaka, Amit Rauthan, H S Murthy, Sunil Karanth
BACKGROUND: Cytoreductive surgery followed by hyper- thermic intraperitoneal chemotherapy (HIPEC) has shown better oncological outcomes in peritoneal surface malignancies (PSM). We assessed the feasibility and perioperative outcomes of this procedure in Indian patients. METHODS: In this prospective observational study from February 2013 to April 2015, we included 56 patients (41 females, 73.2%) with PSM. They had a good performance status, were either treatment-naïve or previously treated by surgery and systemic chemotherapy...
September 2016: National Medical Journal of India
https://www.readbyqxmd.com/read/28000200/-efficacy-and-safety-of-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-advanced-gastric-cancer-a-meta-analysis
#13
Zhentian Ni, Chen Li, Chao Yan, Wentao Liu, Xuexin Yao, Mingmin Chen, Min Yan, Zhenggang Zhu
OBJECTIVE: To systematically evaluate the efficacy and safety of surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced gastric cancer (AGC). METHODS: Clinical control trials about the efficacy and safety of surgery combined with HIPEC in the treatment of advanced gastric cancer published before June 2014 were searched in Embase, PubMed, Cochrane Library, Wanfang database and CNKI database. Quality of enrolled articles was evaluated with the guidelines from Cochrane collaborative network...
December 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27650694/survival-benefit-of-gastrectomy-for-gastric-cancer-with-peritoneal-carcinomatosis-a-propensity-score-matched-analysis
#14
Xiuwen Geng, Hao Liu, Tian Lin, Yanfeng Hu, Hao Chen, Liying Zhao, Tingyu Mou, Xiaolong Qi, Jiang Yu, Guoxin Li
Peritoneal carcinomatosis (PC) is the most frequent pattern of metastasis in stage IV gastric cancer (GC). The study aims to investigate the efficacy of gastrectomy in GC with PC. Clinicopathological data of 518 stage IV GC patients were retrospectively collected in Nanfang Hospital. Among all cases, 312 GC patients with PC (without other site of metastasis) were eligible. Univariate and multivariate analyses were performed to identify the independent prognostic factors. Propensity score matching analysis was performed to balance the characteristics and treatment-related factors...
October 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27563441/hyperthermic-intraperitoneal-chemotherapy-hipec-and-neoadjuvant-chemotherapy-as-prophylaxis-of-peritoneal-carcinosis-from-advanced-gastric-cancer-effects-on-overall-and-disease-free-survival
#15
Federico Coccolini, Andrea Celotti, Marco Ceresoli, Giulia Montori, Michele Marini, Fausto Catena, Luca Ansaloni
BACKGROUND: The possibility to enlarge criteria for intra-peritoneal chemotherapy (IPC) to all patients at high-risk to develop peritoneal carcinosis (i.e., with serosal invasion) is still discussed. METHODS: Retrospective case-control study. Three-groups: advanced-gastric-cancer (AGC) (pT4) without proven carcinosis: prophylactic group (PG), those with PC: treatment group (TG), AGC (pT3-pT4) operated without hyperthermic intraperitoneal chemotherapy (HIPEC), surgery alone group (SG T3, SG T4)...
August 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/27487625/-management-of-peritoneal-carcinomatosis-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#16
Alexandre Balaphas, Valentina Belfontali, Frédéric Ris, Andreas Lanitis, Raphael P H Meier, Marie-Laure Amram, Arnaud Roth, Olivier Huber, Thierry Berney, Philippe Morel
In 2016, peritoneal carcinomatosis can be considered as a chronic disease that can be treated and sometimes cured. Hyperthermic Intra PEritoneal Chemotherapy (HIPEC) is a procedure developed in the eighties. Combined with CytoReductive (CR) surgery, this protocol underwent a considerable expansion in Washington Cancer Institute. CR combined with HIPEC was demonstrated to be the only curative treatment for PseudoMyxoma Peritonei syndrome (PMP). It is actually approved in the management of peritoneal carcinomatosis of ovarian, colorectal, or peritoneal primitive (mesothelioma) origin but is still studied for gastric cancer...
June 15, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/27446587/a-retrospective-analysis-of-hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-with-peritoneal-metastasis
#17
Meiqin Yuan, Zeng Wang, Guinv Hu, Yunshan Yang, Wangxia Lv, Fangxiao Lu, Haijun Zhong
Peritoneal metastasis (PM) is a poor prognostic factor in patients with gastric cancer. The aim of this study was to evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer with PM by retrospective analysis. A total of 54 gastric cancer patients with positive ascitic fluid cytology were included in this study: 23 patients were treated with systemic chemotherapy combined with HIPEC (HIPEC+ group) and 31 received systemic chemotherapy alone (HIPEC- group)...
August 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27362668/cytoreductive-surgery-combined-with-hyperthermic-intraperitoneal-chemoperfusion-for-the-treatment-of-gastric-cancer-a-single-centre-retrospective-study
#18
Yinuo Tu, Yunhong Tian, Zhiyuan Fang, Qiang Ruan, Hongsheng Tang, Xiangliang Zhang, Yinbing Wu, Yan Ding, Shuzhong Cui
AIM: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemoperfusion (HIPEC) is the treatment regime most likely to achieve prolonged survival in patients with peritoneal carcinomatosis from gastroenteric cancer. To date, few publications have focused on the treatment of patients with gastric cancer alone. Several controversies remain unsolved, including the safety and effectiveness of the CRS-HIPEC combination regime, particularly in cases where HIPEC is used as adjuvant treatment after CRS...
September 2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27347669/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-the-management-of-gastrointestinal-cancers-with-peritoneal-metastases-progress-toward-a-new-standard-of-care
#19
REVIEW
Paul H Sugarbaker
Peritoneal metastases from gastrointestinal cancer was, in the past, accepted as an inevitable component of the natural history of these diseases. It is a major cause of intestinal obstruction, fistula formation, and bowel perforation as the recurrent malignancy progresses to a terminal condition. Peritoneal metastases may be caused by full thickness penetration of the bowel wall by the primary cancer or by spilled cancer cells released into the peritoneal space by surgical trauma. Two new surgical technologies that have evolved to manage peritoneal metastases are cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)...
July 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27330364/treatment-of-peritoneal-surface-malignancies-with-hyperthermic-intraperitoneal-chemotherapy-current-perspectives
#20
REVIEW
J Spiliotis, E Halkia, E de Bree
Peritoneal carcinomatosis (ptc) represents advanced malignant disease and has generally been associated with a grim prognosis. Peritoneal surface malignancy is often the major source of morbidity and mortality; it is of major concern in cancer management. Although ptc is categorized as metastatic disease, it represents a special disease pattern considered to be a locoregional disease limited to the abdominal cavity. The combination of cytoreductive surgery (crs) and intraoperative hyperthermic intraperitoneal chemotherapy (hipec) has successfully been used as locoregional treatment for selected patients with ptc from gastric, colorectal, and ovarian cancer; with mesothelioma; and with pseudomyxoma peritonei...
June 2016: Current Oncology
keyword
keyword
98794
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"